FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2013989077> ?p ?o ?g. }

• W2013989077 endingPage "489" @default.
• W2013989077 startingPage "487" @default.
• W2013989077 abstract "To the Editor: Kala-azar (visceral leishmaniasis) is a fatal disease caused by a protozoan parasite Leishmania donovani and transmitted by the female sandfly, Phlebotomus argentipes. In the state of Assam, India, kala-azar epidemics occurred during 1875–1950 and resulted in thousands of deaths in the districts of Kamrup, Garo Hills, Goalpara, and Nagaon (1,2). The disease gradually disappeared from Assam because of the extensive use of DDT in the national malaria elimination program, and results of later entomologic studies indicated that there were no P. argentipes sandflies in this region after DDT use (3). However, sporadic kala-azar cases appeared again in Assam in 2004 (4), and in 2008, we reported a kala-azar outbreak in Kamrup (5), where kala-azar epidemics had occurred during the 1870s (1).At bimonthly intervals during 2012, we conducted house-to-house surveys in 4 villages in the district of Kamrup, 845 households and 4,376 persons. Residents are socioeconomically poor and depend on agriculture and nearby brick kiln industries for their livelihood; persons involved in these industries generally keep cattle, and areas of cow manure provide breeding sites for sandflies. Persons reported with fever for >2 weeks, anemia, weight loss, and palpable spleen or liver and who were negative for malaria were tested for kala-azar by using the rK39 diagnostic kit (InBiOS, Seattle, WA, USA). We obtained bone marrow biopsy samples from selected persons who exhibited the symptoms listed above. A total of 162 persons had positive kala-azar results according to rK39 testing during 2008–2012; of these, 44 (27%) were children. Microscopic examination of bone marrow biopsy samples from 5 persons showed L. donovani parasites. We treated kala-azar case-patients with sodium stibogluconate (SSG). During the survey we recorded 4 suspected cases of post–kala-azar dermal leishmaniasis (PKDL).Case-patient 1, a 16-year-old boy (panel A in Technical Appendix Figure ), was reported positive by rK39 for kala-azar in November 2008. After receiving 30 injections of SSG (20 mg/kg body weight), he became afebrile and his spleen decreased to a nonpalpable size. He gained weight, and hemoglobin improved to reference range. Three years after treatment, hypopigmented macules developed on his face, abdomen, and hands.Case-patient 2 was an 18-year-old woman (Technical Appendix Figure, panel B). Kala-azar was diagnosed in 2011, and she received 30 injections of SSG. One 1 year after completing treatment, hypopigmented macules developed on her face and hands.Case-patient 3 was a 16-year-old girl (Technical Appendix Figure, panel C). In 2008, after test results for kala-azar were positive, she received 30 SSG injections and clinically recovered. Macular hypopigmentation developed on her face and body 3.5 years after treatment.Case-patient 4, a 45-year-old man (Technical Appendix Figure, panel D) was found positive for kala-azar in 2008 and received 17 doses of SSG. He had discontinued treatment because signs and symptoms subsided considerably, and he became afebrile.Case-patients 1–4 were clinically examined to exclude other dermal diseases caused by fungi, vitiligo, and leprosy. These persons were also tested, and found to be negative, for tuberculosis, hepatitis C virus, and hepatitis B surface antigen. We obtained punched skin biopsy samples from each case-patient; a pinch of biopsy samples were dab smeared on glass slides for examination for .L donovani parasites, and remaining samples were stored in RNAlater (QIAGEN, Hilden, Germany). We microscopically examined Giemsa-stained slides and found L. donovani parasite in 1 sample. Using QIAamp DNA Mini Kit (QIAGEN), we isolated parasite DNA from the samples and used it for the first round of PCR with primers 5′-AAATCGGCTCCGAGGCGGGAAAC-3′ and 5′-GGTACACTCTATCAGTAGCAC-3′ as described by Salotra et al. (6). Primers encompassing a 385-bp fragment internal to the 592-bp of L. donovani minicircle kinetoplast DNA having sequence 5′-TCGGACGTGTGTGGATATGGC-3′ and 5′-CCGATAATATAGTATCTCCCG-3′ (7) were used for nested PCR. Three samples were positive (Figure). We treated PKDL case-patients with amphotericin B deoxycholate in accordance with World Health Organization guidelines (8), and these patients recovered clinically.FigureElectrophoretogram of Leishmania donovani kinetoplast DNA-specific PCR products (385 bp) isolated from patients with suspected post–kala-azar dermal leishmaniasis, Assam, India. Lane M, 100-bp DNA ladder; lanes 1–4, suspected post–kala-azar ...Resurgence of kala-azar in the Kamrup district after a 60-year absence poses new challenges to India’s kala-azar elimination program. Of the 162 kala-azar cases detected, many were in children who had no history of visiting other kala-azar–endemic areas. These findings suggest local transmission of infection and are supported by the presence of the vector sandfly during the 2008 outbreak (5).In India, PKDL develops in 5%–15% of treated kala-azar case-patients (9); in Sudan, conversion of kala-azar to PKDL is as high as 50% (10). PKDL cases act as reservoirs for kala-azar. Therefore, effective control depends on active surveillance for kala-azar and PKDL and treatment of kala-azar with antileishmanial drugs in accordance with Government of India guidelines (www.nvbdcp.gov.in/Doc/Guidelines-Diagnosis-Treatment-KA.pdf, www.nvbdcp.gov.in/Doc/PKDL-Guidelines-220512.pdf). Ecologic conditions of the areas where kala-azar outbreaks occurred are conducive to sandfly breeding; thus, regular spraying of DDT is needed. Preventive measures to control spread of kala-azar to other areas of Assam would be an effective step for the kala-azar control program.Technical Appendix: Skin lesions of patients with post–kala-azar dermal leishmaniasis, Assam, India.Click here to view.(104K, pdf)" @default.
• W2013989077 created "2016-06-24" @default.
• W2013989077 creator A5000295666 @default.
• W2013989077 creator A5007230002 @default.
• W2013989077 creator A5039445140 @default.
• W2013989077 creator A5047872768 @default.
• W2013989077 creator A5048451451 @default.
• W2013989077 creator A5081281242 @default.
• W2013989077 creator A5088743908 @default.
• W2013989077 date "2014-03-01" @default.
• W2013989077 modified "2023-09-29" @default.
• W2013989077 title "Kala-azar and Post–Kala-azar Dermal Leishmaniasis, Assam, India" @default.
• W2013989077 cites W2020830292 @default.
• W2013989077 cites W2091631576 @default.
• W2013989077 cites W2095120058 @default.
• W2013989077 cites W2101268804 @default.
• W2013989077 cites W2152475239 @default.
• W2013989077 doi "https://doi.org/10.3201/eid2003.130260" @default.
• W2013989077 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3944866" @default.
• W2013989077 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24565057" @default.
• W2013989077 hasPublicationYear "2014" @default.
• W2013989077 type Work @default.
• W2013989077 sameAs 2013989077 @default.
• W2013989077 citedByCount "5" @default.
• W2013989077 countsByYear W20139890772014 @default.
• W2013989077 countsByYear W20139890772016 @default.
• W2013989077 countsByYear W20139890772018 @default.
• W2013989077 countsByYear W20139890772020 @default.
• W2013989077 countsByYear W20139890772022 @default.
• W2013989077 crossrefType "journal-article" @default.
• W2013989077 hasAuthorship W2013989077A5000295666 @default.
• W2013989077 hasAuthorship W2013989077A5007230002 @default.
• W2013989077 hasAuthorship W2013989077A5039445140 @default.
• W2013989077 hasAuthorship W2013989077A5047872768 @default.
• W2013989077 hasAuthorship W2013989077A5048451451 @default.
• W2013989077 hasAuthorship W2013989077A5081281242 @default.
• W2013989077 hasAuthorship W2013989077A5088743908 @default.
• W2013989077 hasBestOaLocation W20139890771 @default.
• W2013989077 hasConcept C159047783 @default.
• W2013989077 hasConcept C203014093 @default.
• W2013989077 hasConcept C2776555147 @default.
• W2013989077 hasConcept C2778689377 @default.
• W2013989077 hasConcept C2781333301 @default.
• W2013989077 hasConcept C2781417161 @default.
• W2013989077 hasConcept C42972112 @default.
• W2013989077 hasConcept C71924100 @default.
• W2013989077 hasConcept C86803240 @default.
• W2013989077 hasConceptScore W2013989077C159047783 @default.
• W2013989077 hasConceptScore W2013989077C203014093 @default.
• W2013989077 hasConceptScore W2013989077C2776555147 @default.
• W2013989077 hasConceptScore W2013989077C2778689377 @default.
• W2013989077 hasConceptScore W2013989077C2781333301 @default.
• W2013989077 hasConceptScore W2013989077C2781417161 @default.
• W2013989077 hasConceptScore W2013989077C42972112 @default.
• W2013989077 hasConceptScore W2013989077C71924100 @default.
• W2013989077 hasConceptScore W2013989077C86803240 @default.
• W2013989077 hasIssue "3" @default.
• W2013989077 hasLocation W20139890771 @default.
• W2013989077 hasLocation W20139890772 @default.
• W2013989077 hasLocation W20139890773 @default.
• W2013989077 hasLocation W20139890774 @default.
• W2013989077 hasLocation W20139890775 @default.
• W2013989077 hasOpenAccess W2013989077 @default.
• W2013989077 hasPrimaryLocation W20139890771 @default.
• W2013989077 hasRelatedWork W1866137602 @default.
• W2013989077 hasRelatedWork W2037550812 @default.
• W2013989077 hasRelatedWork W2067709645 @default.
• W2013989077 hasRelatedWork W2096156614 @default.
• W2013989077 hasRelatedWork W2133839431 @default.
• W2013989077 hasRelatedWork W2150604586 @default.
• W2013989077 hasRelatedWork W2156560367 @default.
• W2013989077 hasRelatedWork W2318877614 @default.
• W2013989077 hasRelatedWork W2526654304 @default.
• W2013989077 hasRelatedWork W2895003887 @default.
• W2013989077 hasVolume "20" @default.
• W2013989077 isParatext "false" @default.
• W2013989077 isRetracted "false" @default.
• W2013989077 magId "2013989077" @default.
• W2013989077 workType "article" @default.